Xy Capital LTD Bei Gene, Ltd. Transaction History

Xy Capital LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$141.8 - $181.47 $4.2 Million - $5.37 Million	29,616 New	29,616 $4.63 Billion
Q3 2023 Nov 01, 2023	BUY	$179.87 - $225.13 $2.56 Million - $3.2 Million	14,235 Added 1205.33%	15,416 $2.77 Billion
Q2 2023 Jul 28, 2023	SELL	$178.3 - $266.78 $1.51 Million - $2.27 Million	-8,496 Reduced 87.8%	1,181 $211 Million
Q1 2023 May 08, 2023	BUY	$215.53 - $274.5 $1 Million - $1.28 Million	4,659 Added 92.85%	9,677 $2.09 Billion
Q4 2022 Feb 09, 2023	BUY	$125.51 - $229.3 $629,809 - $1.15 Million	5,018 New	5,018 $1.1 Billion

213

45.5M

106K

93.1K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $20.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Xy Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Xy Capital LTD with notifications on news.